CN105567655A - 一种卤醇脱卤酶及其在合成他汀类药物中间体中的应用 - Google Patents
一种卤醇脱卤酶及其在合成他汀类药物中间体中的应用 Download PDFInfo
- Publication number
- CN105567655A CN105567655A CN201410542928.2A CN201410542928A CN105567655A CN 105567655 A CN105567655 A CN 105567655A CN 201410542928 A CN201410542928 A CN 201410542928A CN 105567655 A CN105567655 A CN 105567655A
- Authority
- CN
- China
- Prior art keywords
- halohydrin
- carbon atoms
- halohydrin dehalogenase
- dehalogenase
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010013164 halohydrin dehalogenase Proteins 0.000 title claims abstract description 63
- 238000003786 synthesis reaction Methods 0.000 title abstract description 13
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 title abstract description 10
- 230000015572 biosynthetic process Effects 0.000 title abstract description 8
- 229940079593 drug Drugs 0.000 title abstract description 6
- 239000003814 drug Substances 0.000 title abstract description 6
- 238000006243 chemical reaction Methods 0.000 claims abstract description 35
- 238000000034 method Methods 0.000 claims abstract description 27
- 238000003259 recombinant expression Methods 0.000 claims abstract description 27
- 150000007523 nucleic acids Chemical group 0.000 claims abstract description 23
- 239000013604 expression vector Substances 0.000 claims abstract description 17
- -1 6-substituted-3, 5-dihydroxyhexanoate Chemical class 0.000 claims abstract description 14
- 238000002360 preparation method Methods 0.000 claims abstract description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 32
- 229910052736 halogen Inorganic materials 0.000 claims description 24
- 150000002367 halogens Chemical group 0.000 claims description 24
- 238000006467 substitution reaction Methods 0.000 claims description 21
- 108090000623 proteins and genes Proteins 0.000 claims description 16
- 230000000694 effects Effects 0.000 claims description 13
- 102000004169 proteins and genes Human genes 0.000 claims description 13
- 239000000243 solution Substances 0.000 claims description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 12
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 12
- 229910052801 chlorine Inorganic materials 0.000 claims description 11
- 229910052794 bromium Inorganic materials 0.000 claims description 10
- 229910052740 iodine Inorganic materials 0.000 claims description 10
- 241000588724 Escherichia coli Species 0.000 claims description 9
- 239000003054 catalyst Substances 0.000 claims description 9
- 230000002194 synthesizing effect Effects 0.000 claims description 9
- 125000000217 alkyl group Chemical group 0.000 claims description 8
- 239000003153 chemical reaction reagent Substances 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 8
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
- 108020004707 nucleic acids Proteins 0.000 claims description 8
- 102000039446 nucleic acids Human genes 0.000 claims description 8
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 8
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 7
- 239000013612 plasmid Substances 0.000 claims description 6
- 229910052783 alkali metal Inorganic materials 0.000 claims description 5
- 150000001340 alkali metals Chemical group 0.000 claims description 5
- 239000002773 nucleotide Substances 0.000 claims description 5
- 125000003729 nucleotide group Chemical group 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 4
- 125000005098 aryl alkoxy carbonyl group Chemical group 0.000 claims description 4
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 4
- 125000003118 aryl group Chemical group 0.000 claims description 4
- 125000005228 aryl sulfonate group Chemical group 0.000 claims description 4
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims description 4
- 125000001589 carboacyl group Chemical group 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 4
- 238000012217 deletion Methods 0.000 claims description 4
- 230000037430 deletion Effects 0.000 claims description 4
- 125000005544 phthalimido group Chemical group 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- 125000000539 amino acid group Chemical group 0.000 claims description 3
- 239000008363 phosphate buffer Substances 0.000 claims description 3
- 238000007792 addition Methods 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 230000003100 immobilizing effect Effects 0.000 claims description 2
- 238000007142 ring opening reaction Methods 0.000 claims description 2
- MNWBNISUBARLIT-UHFFFAOYSA-N sodium cyanide Chemical compound [Na+].N#[C-] MNWBNISUBARLIT-UHFFFAOYSA-N 0.000 claims description 2
- 239000013603 viral vector Substances 0.000 claims description 2
- KLWVUDQIPZIXER-UHNVWZDZSA-N (4r,6s)-6-(chloromethyl)-4-hydroxyoxan-2-one Chemical compound O[C@@H]1C[C@@H](CCl)OC(=O)C1 KLWVUDQIPZIXER-UHNVWZDZSA-N 0.000 claims 3
- FIKPWJZUGTVXCO-SFYZADRCSA-N tert-butyl (3r,5s)-6-chloro-3,5-dihydroxyhexanoate Chemical compound CC(C)(C)OC(=O)C[C@H](O)C[C@H](O)CCl FIKPWJZUGTVXCO-SFYZADRCSA-N 0.000 claims 3
- NQTYMGFSEOSJKM-RKDXNWHRSA-N tert-butyl (3r,5r)-6-cyano-3,5-dihydroxyhexanoate Chemical compound CC(C)(C)OC(=O)C[C@H](O)C[C@H](O)CC#N NQTYMGFSEOSJKM-RKDXNWHRSA-N 0.000 claims 2
- 230000010355 oscillation Effects 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract description 13
- 108090000790 Enzymes Proteins 0.000 abstract description 12
- 102000004190 Enzymes Human genes 0.000 abstract description 12
- 230000003197 catalytic effect Effects 0.000 abstract description 9
- 230000007613 environmental effect Effects 0.000 abstract description 4
- 239000000047 product Substances 0.000 description 11
- 239000000758 substrate Substances 0.000 description 11
- 108020004414 DNA Proteins 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 239000000460 chlorine Substances 0.000 description 6
- 238000009396 hybridization Methods 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 5
- 239000000543 intermediate Substances 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 238000006555 catalytic reaction Methods 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- LELOWRISYMNNSU-UHFFFAOYSA-N hydrogen cyanide Chemical compound N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 description 4
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 230000035939 shock Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 108700026244 Open Reading Frames Proteins 0.000 description 3
- 102000018120 Recombinases Human genes 0.000 description 3
- 108010091086 Recombinases Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 150000002118 epoxides Chemical class 0.000 description 3
- 239000013613 expression plasmid Substances 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000008055 phosphate buffer solution Substances 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 230000001131 transforming effect Effects 0.000 description 3
- 239000011534 wash buffer Substances 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 230000002210 biocatalytic effect Effects 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 208000012839 conversion disease Diseases 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- ZAJNMXDBJKCCAT-YFKPBYRVSA-N ethyl (3s)-4-chloro-3-hydroxybutanoate Chemical compound CCOC(=O)C[C@H](O)CCl ZAJNMXDBJKCCAT-YFKPBYRVSA-N 0.000 description 2
- 239000006052 feed supplement Substances 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000012064 sodium phosphate buffer Substances 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 238000011426 transformation method Methods 0.000 description 2
- FJLGEFLZQAZZCD-MCBHFWOFSA-M (3R,5S)-fluvastatin(1-) Chemical compound C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 FJLGEFLZQAZZCD-MCBHFWOFSA-M 0.000 description 1
- KJTLQQUUPVSXIM-ZCFIWIBFSA-M (R)-mevalonate Chemical compound OCC[C@](O)(C)CC([O-])=O KJTLQQUUPVSXIM-ZCFIWIBFSA-M 0.000 description 1
- 0 *CC(CC(C1)O)OC1=O Chemical compound *CC(CC(C1)O)OC1=O 0.000 description 1
- LDLCZOVUSADOIV-UHFFFAOYSA-N 2-bromoethanol Chemical group OCCBr LDLCZOVUSADOIV-UHFFFAOYSA-N 0.000 description 1
- 102000006991 Apolipoprotein B-100 Human genes 0.000 description 1
- 108010008150 Apolipoprotein B-100 Proteins 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- TUCVYDPQEAJSGU-UHFFFAOYSA-N ClCC(CC(CC(=O)OC(C)(C)C)=C=O)=C=O Chemical compound ClCC(CC(CC(=O)OC(C)(C)C)=C=O)=C=O TUCVYDPQEAJSGU-UHFFFAOYSA-N 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
- KJTLQQUUPVSXIM-UHFFFAOYSA-N DL-mevalonic acid Natural products OCCC(O)(C)CC(O)=O KJTLQQUUPVSXIM-UHFFFAOYSA-N 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000000853 LDL receptors Human genes 0.000 description 1
- 108010001831 LDL receptors Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 241001052560 Thallis Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- XLJMAIOERFSOGZ-UHFFFAOYSA-M cyanate Chemical compound [O-]C#N XLJMAIOERFSOGZ-UHFFFAOYSA-M 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- LOQFROBMBSKWQY-ZCFIWIBFSA-N ethyl (3r)-4-cyano-3-hydroxybutanoate Chemical compound CCOC(=O)C[C@H](O)CC#N LOQFROBMBSKWQY-ZCFIWIBFSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229960003765 fluvastatin Drugs 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000003944 halohydrins Chemical class 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000002440 industrial waste Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 229940050906 magnesium chloride hexahydrate Drugs 0.000 description 1
- DHRRIBDTHFBPNG-UHFFFAOYSA-L magnesium dichloride hexahydrate Chemical compound O.O.O.O.O.O.[Mg+2].[Cl-].[Cl-] DHRRIBDTHFBPNG-UHFFFAOYSA-L 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 229960002797 pitavastatin Drugs 0.000 description 1
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 229960002965 pravastatin Drugs 0.000 description 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
- 238000012257 pre-denaturation Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000009465 prokaryotic expression Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 229960000672 rosuvastatin Drugs 0.000 description 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000011218 seed culture Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Landscapes
- Enzymes And Modification Thereof (AREA)
Abstract
Description
Claims (24)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410542928.2A CN105567655B (zh) | 2014-10-14 | 2014-10-14 | 一种卤醇脱卤酶及其在合成他汀类药物中间体中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410542928.2A CN105567655B (zh) | 2014-10-14 | 2014-10-14 | 一种卤醇脱卤酶及其在合成他汀类药物中间体中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105567655A true CN105567655A (zh) | 2016-05-11 |
CN105567655B CN105567655B (zh) | 2020-11-20 |
Family
ID=55878285
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410542928.2A Active CN105567655B (zh) | 2014-10-14 | 2014-10-14 | 一种卤醇脱卤酶及其在合成他汀类药物中间体中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105567655B (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108048438A (zh) * | 2018-02-09 | 2018-05-18 | 浙江宏元药业股份有限公司 | 一种卤代醇脱卤酶突变体及其应用 |
CN109295044A (zh) * | 2018-10-26 | 2019-02-01 | 浙江大学 | 一种卤醇脱卤酶突变体及其应用 |
CN113481179A (zh) * | 2021-06-24 | 2021-10-08 | 江苏阿尔法药业股份有限公司 | 一种脱卤酶和制备方法及在制备阿托伐他汀中间体中的应用 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1859057A4 (en) * | 2005-02-23 | 2009-08-19 | Codexis Inc | HALOHYDRIN ENHANCED DESHALOGENASES AND ASSOCIATED POLYNUCLEOTIDES |
US20100173372A1 (en) * | 2008-12-18 | 2010-07-08 | Codexis, Inc. | Recombinant Halohydrin Dehalogenase Polypeptides |
CN102827853A (zh) * | 2012-09-06 | 2012-12-19 | 江苏阿尔法药业有限公司 | 一种卤醇脱卤酶基因突变体及其应用 |
CN102978193A (zh) * | 2012-11-13 | 2013-03-20 | 浙江工业大学 | 卤醇脱卤酶、编码基因、载体、菌株及应用 |
CN103014082A (zh) * | 2012-12-20 | 2013-04-03 | 苏州汉酶生物技术有限公司 | (r)-4-氰基-3-羟基丁酸乙酯的生物制备方法 |
CN103627776A (zh) * | 2013-12-10 | 2014-03-12 | 江南大学 | 一种制备s-2-(4-硝基苯基)环氧乙烷的方法 |
CN103695486A (zh) * | 2014-01-03 | 2014-04-02 | 黄冈华阳药业有限公司 | 一种(3r,5r)-6-氰基-3,5-二羟基己酸叔丁酯的生物制备方法 |
CN104087547A (zh) * | 2014-07-03 | 2014-10-08 | 浙江大学 | 一种工程菌及制备(3r,5r)6-氰基-3,5-二羟基己酸叔丁酯的方法 |
-
2014
- 2014-10-14 CN CN201410542928.2A patent/CN105567655B/zh active Active
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1859057A4 (en) * | 2005-02-23 | 2009-08-19 | Codexis Inc | HALOHYDRIN ENHANCED DESHALOGENASES AND ASSOCIATED POLYNUCLEOTIDES |
US20100173372A1 (en) * | 2008-12-18 | 2010-07-08 | Codexis, Inc. | Recombinant Halohydrin Dehalogenase Polypeptides |
CN102827853A (zh) * | 2012-09-06 | 2012-12-19 | 江苏阿尔法药业有限公司 | 一种卤醇脱卤酶基因突变体及其应用 |
CN102978193A (zh) * | 2012-11-13 | 2013-03-20 | 浙江工业大学 | 卤醇脱卤酶、编码基因、载体、菌株及应用 |
CN103014082A (zh) * | 2012-12-20 | 2013-04-03 | 苏州汉酶生物技术有限公司 | (r)-4-氰基-3-羟基丁酸乙酯的生物制备方法 |
CN103627776A (zh) * | 2013-12-10 | 2014-03-12 | 江南大学 | 一种制备s-2-(4-硝基苯基)环氧乙烷的方法 |
CN103695486A (zh) * | 2014-01-03 | 2014-04-02 | 黄冈华阳药业有限公司 | 一种(3r,5r)-6-氰基-3,5-二羟基己酸叔丁酯的生物制备方法 |
CN104087547A (zh) * | 2014-07-03 | 2014-10-08 | 浙江大学 | 一种工程菌及制备(3r,5r)6-氰基-3,5-二羟基己酸叔丁酯的方法 |
Non-Patent Citations (4)
Title |
---|
R.M.DE JONG等: "Structure and mechanism of a bacterial haloalcohol dehalogenase: a new variation of the short-chain dehydrogenase/reductase fold without an NAD(P)H binding site", 《THE EMBO JOURNAL》 * |
VAN HYLCKAMA VLIEG等: "halohydrin dehalogenase [Agrobacterium tumefaciens],Accission No. AAK92099.1", 《GENBANK》 * |
聂洪丽等: "富集培养及高质量DNA 提取有利于从土壤宏基因组中获取新卤醇脱卤酶基因", 《生物技术通讯》 * |
郑楷等: "多功能生物催化剂-卤醇脱卤酶的研究进展", 《化工学报》 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108048438A (zh) * | 2018-02-09 | 2018-05-18 | 浙江宏元药业股份有限公司 | 一种卤代醇脱卤酶突变体及其应用 |
CN108048438B (zh) * | 2018-02-09 | 2020-08-18 | 浙江宏元药业股份有限公司 | 一种卤代醇脱卤酶突变体及其应用 |
CN109295044A (zh) * | 2018-10-26 | 2019-02-01 | 浙江大学 | 一种卤醇脱卤酶突变体及其应用 |
CN113481179A (zh) * | 2021-06-24 | 2021-10-08 | 江苏阿尔法药业股份有限公司 | 一种脱卤酶和制备方法及在制备阿托伐他汀中间体中的应用 |
Also Published As
Publication number | Publication date |
---|---|
CN105567655B (zh) | 2020-11-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7132267B2 (en) | Enzymatic processes for the production of 4-substituted 3-hydroxybutyric acid derivatives and vicinal cyano, hydroxy substituted carboxylic acid esters | |
US8980592B2 (en) | Process for the enantioselective enzymatic reduction of hydroxy keto compounds | |
US8404870B2 (en) | ((2S,4R)-4,6-dihydroxytetrahydro-2H-pyran-2-yl)methyl carboxylate and process for the production thereof | |
CN105567655B (zh) | 一种卤醇脱卤酶及其在合成他汀类药物中间体中的应用 | |
CN105567652B (zh) | 一种酮还原酶及其在不对称合成手性羟基化合物中的应用 | |
JP6921258B2 (ja) | ピタバスタチンカルシウムの製造方法 | |
JP2021063087A (ja) | ロスバスタチンカルシウム及びその中間体の製造方法 | |
CN105441401B (zh) | 一种单胺氧化酶及其在合成手性氮杂双环化合物中的应用 | |
CN115404250B (zh) | 一种利用还原方式制备(s)-尼古丁的方法 | |
CN109971802B (zh) | 一种酶法拆分制备(s)-1,2,3,4-四氢异喹啉-1-甲酸及其衍生物的方法 | |
CN114934061A (zh) | 工程菌及其在全细胞催化酮基泛解酸内酯生产d-泛解酸内酯中的应用 | |
CN113388600B (zh) | 一种醛肟脱水酶及其在催化合成芳香腈类化合物中的应用 | |
CN105087704B (zh) | 一种可调控多酶级联反应用于合成光学纯烯丙型环氧酮或醇 | |
US20210087595A1 (en) | Method for preparing (s)-1-benzyl-1,2,3,4,5,6,7,8-octahydroisoquinoline compound | |
CN105624127B (zh) | 一种葡萄糖脱氢酶及其在合成他汀类药物中间体中的应用 | |
EP1367132B1 (en) | Process for preparation of optically active propoxyaniline derivatives | |
KR20070048741A (ko) | 디아릴사이클로알킬 유도체의 제조방법 | |
CN113025671B (zh) | 苜蓿中华根瘤菌来源的腈水合酶在制备酰胺吡嗪类化合物中的应用 | |
CN115572746A (zh) | 一种双相体系下化学酶法级联催化酰胺类化合物的一锅法合成工艺 | |
CN114774382A (zh) | 立体选择性制备6,6-二甲基-3-氮杂双环[3.1.0]己烯化合物的方法 | |
KR20090131968A (ko) | 샤페론 단백질의 동시발현을 이용한 고활성 유전자 재조합전세포 생촉매 제조방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20180207 Address after: 201203 Chinese (Shanghai) free trade zone fanchun Road No. 400 Building 1 room 436 4 Applicant after: ABIOCHEM BIOTECHNOLOGY Co.,Ltd. Address before: Pu Si Road in Pukou District of Nanjing City, Jiangsu province 210032 No. 18 Taishan street, science and Technology Innovation Park 1 building 408 room Applicant before: NANJING ABIOCHEM BIOMEDICAL TECHNOLOGY CO.,LTD. |
|
TA01 | Transfer of patent application right | ||
CB02 | Change of applicant information | ||
CB02 | Change of applicant information |
Address after: Room 3114, Building B, 555 Dongchuan Road, Minhang District, Shanghai, 200240 Applicant after: ABIOCHEM BIOTECHNOLOGY Co.,Ltd. Address before: Room 436, 4th floor, No. 400 Fangchun Road, China (Shanghai) Free Trade Pilot Area Applicant before: ABIOCHEM BIOTECHNOLOGY Co.,Ltd. |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP03 | Change of name, title or address |
Address after: Room 3114, Building B, 555 Dongchuan Road, Minhang District, Shanghai, 200241 Patentee after: Ecolab Biotechnology (Shanghai) Co.,Ltd. Address before: Room 3114, building B, 555 Dongchuan Road, Minhang District, Shanghai 200240 Patentee before: ABIOCHEM BIOTECHNOLOGY Co.,Ltd. |
|
CP03 | Change of name, title or address | ||
CP01 | Change in the name or title of a patent holder |
Address after: Room 3114, Building B, 555 Dongchuan Road, Minhang District, Shanghai, 200241 Patentee after: Yikelai Biotechnology (Group) Co.,Ltd. Address before: Room 3114, Building B, 555 Dongchuan Road, Minhang District, Shanghai, 200241 Patentee before: Ecolab Biotechnology (Shanghai) Co.,Ltd. |
|
CP01 | Change in the name or title of a patent holder |